2765654-79-1
Chemical Structure
STF-3600
- CAS No.: 2765654-79-1
- Formula:C24H21N5
- Molecular Weight:379.46
InChIKey: DPNPYGJVEWBPON-QFIPXVFZSA-N
SMILES: CC1=CC(C2=NNC3=CC=C(C=C23)N[C@@H]4C5=CC=C(C#N)C=C5CCC4)=CC=N1
Biological Activity: STF-3600 is a LRRK2G2019S inhibitor with an IC50 of 0.9 nM against the human target. It has oral activity and can cross the blood-brain barrier. STF-3600 selectively inhibits kinase activity, including autophosphorylation at Ser935 and Ser1292, as well as phosphorylation of the endogenous substrate Rab10 at Thr73. STF-3600 inhibits vacuolization of type II pulmonary epithelial cells in wild-type/heterozygous mice, while it induces this vacuolization phenotype in homozygous mice. STF-3600 can be used in Parkinson's disease research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
STF-3600 | STF-3600 is a LRRK2G2019S inhibitor with an IC50 of 0.9 nM against the human target. It has oral activity and can cross the blood-brain barrier. STF-3600 selectively inhibits kinase activity, including autophosphorylation at Ser935 and Ser1292, as well as phosphorylation of the endogenous substrate Rab10 at Thr73. STF-3600 inhibits vacuolization of type II pulmonary epithelial cells in wild-type/heterozygous mice, while it induces this vacuolization phenotype in homozygous mice. STF-3600 can be used in Parkinson's disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
